Browse studies, page 1165

Page 1165 of 1,203, newest first. Search them all at once, ranked by relevance, in Evidence Hub.

• Current trends in the epidemiology of multidrug-resistant and beta-lactamase-producing Pseudomonas aeruginosa in Asia and Africa: a systematic review and meta-analysis PeerJ, 2025
• Efficacy and safety of different polymyxin-containing regimens for the treatment of pneumonia caused by multidrug-resistant gram-negative bacteria: a systematic review and network meta-analysis Critical care (London, England), 2024
• Definitional ambiguity and the dual threat of Hypervirulent Klebsiella pneumoniae infections: a systematic review and meta-analysis Infection, 2026
• Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients Clinical and experimental medicine, 2025
• Once a DAY levofloxacin in the treatment of mild to moderate and severe community-acquired pneumonia in adults Infectious Diseases in Clinical Practice, 1998
• Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis Frontiers in Medicine, 2018
• Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial Clinical Infectious Diseases, 2008
• Clinical presentation of Legionella pneumonia: Evaluation of clinical scoring systems and therapeutic efficacy Journal of Infection and Chemotherapy, 2017
• Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila Journal of Antimicrobial Chemotherapy, 2001
• ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia Intensive Care Medicine, 2023
• Update on the treatment of Pseudomonas aeruginosa pneumonia Journal of Antimicrobial Chemotherapy, 2009
• Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study European Respiratory Journal, 2009
• Nursing Home–Acquired Pneumonia Clinical Infectious Diseases, 2002
• Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome Thorax, 2004
• A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia Clinical Therapeutics, 2002
• Etiology of community-acquired pneumonia in adults: a systematic review Pneumonia, 2020
• Efficacy and safety of moxifloxacin in patients with nursing and healthcare-associated pneumonia PubMed, 2013
• Update of the treatment of nosocomial pneumonia in the ICU Critical Care, 2020
• Severe Community-acquired Pneumonia Due to Staphylococcus aureus , 2003–04 Influenza Season Emerging infectious diseases, 2006
• Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients Respiratory Medicine, 2006
• In vivo activity of levofloxacin alone or in combination with imipenem or amikacin in a mouse model of Acinetobacter baumannii pneumonia Journal of Antimicrobial Chemotherapy, 2000
• Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the Working Party on Hospital-Acquired Pneumonia of the British Society for Antimicrobial Chemotherapy Journal of Antimicrobial Chemotherapy, 2008
• Duration of Antibiotic Treatment in Community-Acquired Pneumonia JAMA Internal Medicine, 2016
• Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia Journal of Clinical Pharmacy and Therapeutics, 2009
• Clinical Practice Guidelines for Hospital‐Acquired Pneumonia and Ventilator‐Associated Pneumonia in Adults Canadian Journal of Infectious Diseases and Medical Microbiology, 2007
• Corticosteroids for pneumonia Cochrane Database of Systematic Reviews, 2017
• A critical review of the fluoroquinolones: focus on respiratory infections Drugs, 2002
• A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia Clinical Therapeutics, 2002
• Linezolid in Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia: A Randomized, Controlled Study Clinical Infectious Diseases, 2012
• A Multicenter, Randomized Study Comparing the Efficacy and Safety of Intravenous and/or Oral Levofloxacin versus Ceftriaxone and/or Cefuroxime Axetil in Treatment of Adults with Community-Acquired Pneumonia Infectious Diseases in Clinical Practice, 1998
• Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia Diagnostic Microbiology and Infectious Disease, 2008
• British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011 Thorax, 2011
• Update of Practice Guidelines for the Management of Community-Acquired Pneumonia in Immunocompetent Adults Clinical Infectious Diseases, 2003
• Community‐Acquired Pneumonia in Adults: Guidelines for Management Clinical Infectious Diseases, 1998
• BTS guidelines for the management of community acquired pneumonia in adults: update 2009 Thorax, 2009
• Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia Treatments in Respiratory Medicine, 2004
• Pneumococcal Bacteremia with Especial Reference to Bacteremic Pneumococcal Pneumonia Annals of Internal Medicine, 1964
• International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia European Respiratory Journal, 2017
• Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults Clinical Infectious Diseases, 2000
• A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Intravenous Tigecycline Vs Intravenous Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia ClinicalTrials.gov · COMPLETED, 2005
• An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia ClinicalTrials.gov · COMPLETED, 2017
• Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents ClinicalTrials.gov · COMPLETED, 2021
• A Multicenter, Randomized, Open Label Study to Compare the Safety and Efficacy of Levofloxacin With That of Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia ClinicalTrials.gov · COMPLETED, 2001
• A Multinational, Prospective, Randomized, Double-blind Study to Investigate the Efficacy and Safety of Sequential Intravenous/Oral Moxifloxacin in Comparison to Intravenous Levofloxacin Plus Intravenous Ceftriaxone Followed by Oral Levofloxacin, in the Treatment of Patients With Severe Community-acquired Pneumonia ClinicalTrials.gov · COMPLETED, 2005
• A Phase 2, Multi-Dose, Double-Blind, Double-Dummy, Active-Control, Randomized Study to Evaluate the Safety, Efficacy and Pharmacokinetic Profile of Two Dosing Regimens of Zabofloxacin for the Treatment of Community-Acquired Pneumonia of Moderate Severity ClinicalTrials.gov · TERMINATED, 2012
• A Multicenter, Open-label, Randomized, Active-controlled, Parallel Group, Pivotal Study to Investigate the Efficacy, Safety and Tolerability, and Pharmacokinetics of Murepavadin Combined With One Anti-pseudomonal Antibiotic Versus Two Anti-pseudomonal Antibiotics in Adult Subjects With Ventilator-associated Bacterial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa ClinicalTrials.gov · TERMINATED, 2019
• A Randomized, Multicenter, Open Label Trial Comparing Intravenous Zithromax® (Azithromycin) Plus Intravenous Rocephin® (Ceftriaxone) Followed By Oral Zithromax® (Azithromycin) With Intravenous Levaquin® (Levofloxacin) Followed By Oral Levaquin® (Levofloxacin) For The Treatment Of Moderate To Severely Ill Hospitalized Subjects With Community-Acquired Pneumonia ClinicalTrials.gov · COMPLETED, 2002
• Antibiotic Treatment of Community-acquired Pneumonia: a Prospective Comparison of Dutch Guideline Advices ClinicalTrials.gov · COMPLETED, 2014
• A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral CEM-101 Compared to Oral Levofloxacin in the Treatment of Patients With Community-Acquired Bacterial Pneumonia ClinicalTrials.gov · COMPLETED, 2011
• A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of Antibacterial Prophylaxis for Prevention of Infections in Azacitidine Treated Myelodysplastic Syndrome Patients ClinicalTrials.gov · COMPLETED, 2022
• A Multicenter, Active-Controlled, Randomized Study To Evaluate The Safety And Efficacy Of Levofloxacin Versus Ceftriaxone Sodium Or Cefuroxime Axetil In The Treatment Of Community-Acquired Pneumonia In Adults ClinicalTrials.gov · COMPLETED, 1995
• A Phase 3, Multicenter, Randomized, Double-Blind, Comparative Study Of The Efficacy And Safety Of Tigecycline Vs Levofloxacin To Treat Subjects Hospitalized With Community-Acquired Pneumonia ClinicalTrials.gov · COMPLETED, 2005
• A Multicenter, Randomized, Double-Blind, Double-Dummy Comparative Trial of Azithromycin SR Versus Levofloxacin for the Treatment of Mild to Moderate Community-Acquired Pneumonia in Adults ClinicalTrials.gov · COMPLETED, 2004
• A Multi-center, Randomized, Double-blind, Double-dummy Parallel-controlled Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP) ClinicalTrials.gov · COMPLETED, 2010
• Non-Adherence in Adult Male Patients with Community-Acquired Pneumonia: Relative Forgiveness of Amoxicillin versus Respiratory Fluoroquinolones Antibiotics, 2023
• Therapeutic experience with levofloxacin in pneumonia and COPD ˜Le œInfezioni in medicina, 2009
• Effect of ethanol on fluoroquinolone efficacy in a rat model of pneumococcal pneumonia Antimicrobial Agents and Chemotherapy, 2006
• BMS-284756 (T-3811ME) a new fluoroquinolone: in vitro activity against Legionella, efficacy in a guinea pig model of L. pneumophila pneumonia and pharmacokinetics in guinea pigs Journal of Antimicrobial Chemotherapy, 2001
• Evaluation of the Efficacy of Novel Drugs and Combinations Against Extensively- and Pan-Drug Resistant Acinetobacter baumannii Isolates Research Posters, 2024
• Biosynthesis, characterization, and antibiofilm activity of copper-oxide nanoparticles using a mixture of Klebsiella pneumonia and Staphylococcus aureus supernatant Iraqi Journal of Science, 2026
• Abiflox efficacy in complex therapy of patients with community acquired pneumonia DOAJ (DOAJ: Directory of Open Access Journals), 2013
• Correction to: Dunbar LM, Khashab MM, Kahn JB et al. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20(4): 555-563 Current Medical Research and Opinion, 2004
• Outcome of Levofloxacin in the Treatment of Lower Respiratory Tract Infection Scholars Journal of Applied Medical Sciences, 2024
• Efficacy of the combination of levofloxacin plus ceftazidime in the treatment of hospital-acquired pneumonia in the intensive care unit International Journal of Antimicrobial Agents, 2006
• Efficacy of piperacillin-tazobactam combined with levofloxacin for treatment of severe community acquired pneumonia Medical Journal of West China, 2009
• Clinical Efficacy of Levofloxacin and Azithromycinin in the Treatment of Mycoplasma Pneumonia Zhongguo yaofang, 2010
• Efficacy and safety of high dosage levofloxacin injection in the treatment of hospital-acquired pneumonia in intensive care unit Chinese Journal of Infection Control, 2010
• Microbiological Efficacy of Levofloxacin for Treatment of Community-Acquired Pneumonia Due to Chlamydia pneumoniae Antimicrobial Agents and Chemotherapy, 2000
• A randomized, open, multicenter clinical study on the short course of intravenous infusion of 750 mg of levofloxacin and the sequential standard course of intravenous infusion/oral administration of 500 mg of levofloxacin for treatment of community-acquired pneumonia Journal of Thoracic Disease, 2016
• A Prospective Study of the Efficacy, Safety and Pharmacokinetics of Enteral Moxifloxacin in the Treatment of Hemodialysis Patients with Pneumonia Internal medicine, 2017
• Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Levofloxacin versus Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin- Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adults Clinical Infectious Diseases, 2004
• Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens Current Medical Research and Opinion, 2004
• Low-Dose Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis jirovecii Pneumonia in a Critically Ill Patient with HIV/TB Coinfection: Pharmacokinetics and Clinical Outcomes Infection and Drug Resistance, 2025
• Efficacy analysis of Levofloxacin combined with Tanreqing injection in treatment of bacterial pneumonia Medical Journal of West China, 2011
• Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin Diagnostic microbiology and infectious disease, 2009
• Propensity-Matched Comparison of Timely vs Delayed Antibiotic Therapy in Stenotrophomonas maltophilia Pneumonia Open Forum Infectious Diseases, 2025
• Efficacy analysis of Tanreqing combined with Levofloxacin on treatment of community-acquired pneumonia 2012
• Comparative efficacy of levofloxacin and ceftriaxone in the treatment of community acquired pneumonia in children Open Journal of Pediatrics, 2013
• Impact of qnrA1, qnrB1 and qnrS1 on the efficacy of ciprofloxacin and levofloxacin in an experimental pneumonia model caused by Escherichia coli with or without the GyrA mutation Ser83Leu Journal of Antimicrobial Chemotherapy, 2013
• The antibiotic efficacy of levofloxacin tablet was determined utilizing a verification method that included computational and experimental techniques. DFT, UV-VIS, and HPLC-20 AD International journal of scientific and research publications, 2022
• A Monte Carlo pharmacokinetic/pharmacodynamic simulation to evaluate the efficacy of minocycline, tigecycline, moxifloxacin, and levofloxacin in the treatment of hospital-acquired pneumonia caused by Stenotrophomonas maltophilia Infectious Diseases, 2015
• Levofloxacin versus amoxycillin/clavulanic acid combined with azithromycin in treatment of community acquired pneumonia medRxiv, 2023
• Efficacy of Pudilan Xiaoyan Oral Liquid in the treatment of pneumonia induced by drug-resistant Pseudomonas aeruginosa Infectious Diseases Research, 2024
• Evaluating the Clinical Effectiveness of Third-Generation Cephalosporins Combined with Levofloxacin for Treating Community-Acquired Pneumonia in Elderly Patients Alternative Therapies in Health and Medicine, 2024
• Quantitative performance of humanized serum and epithelial lining fluid exposures of tigecycline and levofloxacin against a challenge set of Klebsiella pneumoniae and Pseudomonas aeruginosa in a standardized neutropenic murine pneumonia model Journal of Antimicrobial Chemotherapy, 2024
• The efficacy of antimicrobial therapies in the treatment of mixed biofilms formed between Candida albicans and Porphyromonas gingivalis during epithelial cell infection in the aspiration pneumonia model Medical Microbiology and Immmunology, 2025
• Clinical Effects of Moxifloxacin and Levofloxacin in the Treatment of Elderly Patients with Community-Acquired Pneumonia Journal of Clinical and Nursing Research, 2025
• Efficacy of Azithromycin Injection Combined with Levofloxacin Capsule and Ambroxol Injection in the Treatment of Mycoplasma Pneumonia Journal of experimental and clinical application of Chinese medicine, 2024
• Comparative Efficacy of Levofloxacin Versus Amoxycillin/Clavulanic Acid Combined with Azithromycin in Treatment of Community-Acquired Pneumonia Annals of Innovation in Medicine, 2024
• Cost analysis of a sequential antimicrobial therapy protocol in patients with pneumonia: A multicenter study PloS one, 2026
• Long-term trends in ceftolozane-tazobactam susceptibility among gram-negative pathogens in the United States: a nine-year SMART analysis (2016-2024) JAC-antimicrobial resistance, 2026
• Phage-antibiotic combination: a possible approach to combatting multidrug-resistant Klebsiella pneumoniae AMB Express, 2026
• Evolving antimicrobial resistance patterns in group B streptococci: A five-year study in a high-risk pregnancy referral center in northeastern Brazil Revista da Sociedade Brasileira de Medicina Tropical, 2026
• Extracorporeal near-infrared-activated antimicrobial photodynamic therapy for pneumonia using an ICG-polymer formulation Biophotonics discovery, 2026
• Antibiotics accumulate in Klebsiella pneumoniae liver abscesses but fail to eliminate antibiotic-tolerant populations Proceedings of the National Academy of Sciences of the United States of America, 2025
• Risk Factors Associated with Mortality in Nosocomial Stenotrophomonas maltophilia Pneumonia: A Single-Center Retrospective Study Mediterranean journal of hematology and infectious diseases, 2026
• Application of Metagenomic Next-Generation Sequencing in the Diagnosis of Pneumonia in Patients With Cancer Cancer medicine, 2026
• Molecular insights into macrolide resistant Mycoplasma pneumoniae isolates from outpatient clinics in Tehran, Iran Scientific reports, 2026
• A New Preview of Antibiotic-resistant Spectrum in Community-acquired Pneumonia: A Cross-Sectional Study from Iraq The open respiratory medicine journal, 2026
• Case Report: Fatal osimertinib-related interstitial lung disease during adjuvant therapy after left pneumonectomy in a patient with lung adenocarcinoma undergoing maintenance hemodialysis Frontiers in oncology, 2026